Trial Profile

A Phase 3, Three-Arm, Randomized, Open-Label Study of Interferon Alfa Alone, CCI-779 Alone, and the Combination of Interferon Alfa and CCI-779 in First-Line Poor-Prognosis Subjects With Advanced Renal Cell Carcinoma.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 11 Nov 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 Mar 2010 Results from a quality-adjusted survival analysis presented at the 2010 Genitourinary Cancers Symposium
05 Mar 2010 Results of an analysis of serum LDH as a predictive biomarker for mTOR inhibition in patients with mRCC were presented at ASCO 2010 Genitourinary Cancers Symposium.
21 Nov 2009 New source identified and integrated (M.D. Anderson Cancer Center, 2003-0924).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com